Table 1 Baseline characteristics of enrolled patients (N = 116)
Characteristic | n (%), unless otherwise specified |
|---|---|
Sex, n(%) | |
 Male | 74 (64) |
 Female | 42 (36) |
Age in years, n(%) | |
 15–19 | 1 (1) |
 20–29 | 19 (16) |
 30–39 | 55 (47) |
 40–49 | 43 (26) |
 ≥ 50 | 11 (10) |
Educational attainment, n(%) (N = 114) | |
 No formal education | 5 (4) |
 Primary school | 51 (44) |
 Intermediate school | 50 (44) |
 High school or higher | 8 (8) |
Kaposi stage, n(%) | |
 T1S0 | 80 (69) |
 T1S1 | 31 (26) |
 T0S1 | 2 (2) |
 T0S0 | 3 (3) |
Lymphedema present at enrolment | 83 (72) |
Time since HIV diagnosis in months, n(%) | |
 0–5 | 53 (46) |
 6–11 | 13 (11) |
 12–23 | 18 (16) |
 ≥ 24 | 32 (28) |
Time on ART in months, n(%) | |
 0–5 | 62 (53) |
 6–11 | 13 (11) |
 12–23 | 16 (14) |
 ≥ 24 | 25 (22) |
ART regimen, n(%) | |
 Efavirenz-based | 107 (92) |
 Nevirapine-based | 3 (3) |
 Lopinavir/ritonavir or atazanavir-based | 6 (5) |
On treatment for TB, n(%) | 19 (16) |
Laboratory values, median (IQR) | |
 CD4 (cells/mm3) | 218 (73–448) |
 Serum Hemoglobin (g/dl) | 11.0 (9.8–12.4) |
 Platelets (103 cells/μl) | 284 (222–360) |
 Absolute neutrophil count (103 cells/μl) | 2.7 (2.0–3.6) |
 Creatinine (mg/dl) | 0.8 (0.6–1.0) |
 Alanine aminotransferase (U/L) | 11 (6–17) |